Coronavirus Disease
8
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
ImmuneSense™ COVID-19 Cross-Reactivity Study
LAEH Formulation Nasal Spray to Reduce Viral Load
Observational Study of COVID-19 Treatment Efficacy
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
Post COVID-19 Functional Status in Egypt
Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt